DDX41 and myeloid sarcoma: A few studies performed to evaluate the association between HERVs and MAP in autoimmune diseases reported a partial decrease of anti-MAP Abs in multiple sclerosis (MS) following natalizumab treatment which efficiently reduced levels of Abs targeting HERV-WEnv24.